{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:56:44Z","timestamp":1774263404313,"version":"3.50.1"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The population pharmacokinetics of pyrimethamine (PYR) and sulfadoxine (SDX) for a group of 32 children with congenital toxoplasmosis was investigated by nonparametric modeling analysis. A one-compartment model was used as the structural model, and individual pharmacokinetic parameters were estimated by Bayesian modeling. PYR (1.25 mg\/kg of body weight) and SDX (25 mg\/kg) were administered orally every 10 days for 1 year, with adjustment of the dose to body weight every 3 months. Drug concentrations were measured by high-performance liquid chromatography. A total of 101 measurements in serum were available for both drugs. Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h\n            <jats:sup>\u22121<\/jats:sup>\n            , 4.379 liters\/kg, 0.00839 h\n            <jats:sup>\u22121<\/jats:sup>\n            , and 5.5 days for PYR and 1.659 h\n            <jats:sup>\u22121<\/jats:sup>\n            , 0.392 liters\/kg, 0.00526 h\n            <jats:sup>\u22121<\/jats:sup>\n            , and 6.6 days for SDX, respectively. Wide interindividual variability was observed. The estimated minimum and maximum concentrations of PYR in serum differed 8- and 25-fold among patients, respectively, and those of SDX differed 4- and 5-fold, respectively. Increases in the concentration of PYR were observed for eight children, and increases in the SDX concentration were observed for seven children. Serum PYR-SDX concentrations are unpredictable even when the dose is standardized for body weight. The concentrations of the PYR-SDX combination that are most efficacious for children have not yet been established. A model such as ours, associated with long-term follow-up, is needed to study the correlation between exposure to these two drugs and clinical outcome in children.\n          <\/jats:p>","DOI":"10.1128\/aac.48.10.3794-3800.2004","type":"journal-article","created":{"date-parts":[[2004,9,23]],"date-time":"2004-09-23T19:02:50Z","timestamp":1095966170000},"page":"3794-3800","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Population Pharmacokinetics of Pyrimethamine and Sulfadoxine in Children Treated for Congenital Toxoplasmosis"],"prefix":"10.1128","volume":"48","author":[{"given":"Ste\u0301phane","family":"Corvaisier","sequence":"first","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Charpiat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Mounier","sequence":"additional","affiliation":[{"name":"Desgenettes Army Teaching Hospital, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Wallon","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Croix-Rousse Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Leboucher","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounzer","family":"Al Kurdi","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Croix-Rousse Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Franc\u0327ois","family":"Chaulet","sequence":"additional","affiliation":[{"name":"Desgenettes Army Teaching Hospital, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franc\u0327ois","family":"Peyron","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Croix-Rousse Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2125.1980.tb01798.x","volume":"10","year":"1980","unstructured":"Ahmad, R. A., and H. J. Rogers. 1980. Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. Br. J. Clin. Pharmacol.10:519-524.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_1_3_2","first-page":"185","volume":"309","year":"1991","unstructured":"Akintonwa, A., and O. Obodozie. 1991. Effect of activated charcoal on the disposition of sulphadoxine. Arch. Int. Pharmacodyn. Ther.309:185-192.","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-4347(97)00264-8","volume":"698","year":"1997","unstructured":"Astier, H., C. Renard, V. Cheminel, O. Soares, C. Mounier, F. Peyron, and J. F. Chaulet. 1997. Simultaneous determination of pyrimethamine and sulphadoxine in human plasma by high-performance liquid chromatography after automated liquid-solid extraction. J. Chromatogr. B698:217-223.","journal-title":"J. Chromatogr. B"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00007691-198706000-00013","volume":"9","year":"1987","unstructured":"Bergqvist, Y., E. Hjelm, and L. Rombo. 1987. Sulfadoxine assay using capillary blood samples dried on filter paper\u2014suitable for monitoring of blood concentrations in the field. Ther. Drug Monit.9:203-207.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_1_6_2","first-page":"685","volume":"51","year":"1996","unstructured":"Bourget, P., A. Lesne-Hulin, F. Forestier, V. Desmaris, and E. Dulac. 1996. Pr\u00e9vention de la toxoplasmose cong\u00e9nitale par la spiramycine: int\u00e9r\u00eat et limite du dosage dans le liquide amniotique. Therapie51:685-687.","journal-title":"Therapie"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2002.00899.x"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00003088-199426050-00005","volume":"26","year":"1994","unstructured":"Butler, D. R., R. J. Kuhn, and M. H. Chandler. 1994. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet.26:374-395.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_9_2","first-page":"329","volume":"6","year":"1978","unstructured":"Cavallito, J. C., C. A. Nichol, W. D. Brenckman, R. L. Deangelis, D. R. Stickney, W. S. Simmons, and C. W. Sigel. 1978. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab. Dispos.6:329-337.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0020-7101(94)90113-9","volume":"36","year":"1994","unstructured":"Charpiat, B., and V. Br\u00e9ant. 1994. Another suggestion for measuring predictive performance for aminoglycoside therapy. Intern. J. Bio-Med. Comput.36:161-162.","journal-title":"Intern. J. Bio-Med. Comput."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.303"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2575-2577.2000"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03258448","volume":"5","year":"1993","unstructured":"Dodge, W., R. W. Jelliffe, C. J. Richardson, R. Bellanger, J. Hokanson, and W. Snodgrass. 1993. Population pharmacokinetic models: measures of central tendency. Drug Investig.5:206-211.","journal-title":"Drug Investig."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238499"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00007691-199103000-00010","volume":"13","year":"1991","unstructured":"Edstein, M. D., I. D. Lika, T. Chongsuphajaisiddhi, A. Sabchareon, and H. K. Webster. 1991. Quantitation of Fansimef components (mefloquine + sulfadoxine + pyrimethamine) in human plasma by two high-performance liquid chromatographic methods. Ther. Drug Monit.13:146-151.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.1990.tb03773.x","volume":"30","year":"1990","unstructured":"Edstein, M. D., K. H. Rieckmann, and J. R. Veenendaal. 1990. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. Br. J. Clin. Pharmacol.30:259-265.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1345\/aph.1C427","volume":"37","year":"2003","unstructured":"Escobar, I., M. Campo, J. Martin, C. Fernandez-Shaw, F. Pulido, and R. Rubio. 2003. Factors affecting patient adherence to highly active antiretroviral therapy. Ann. Pharmacother.37:775-781.","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1580"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199223010-00001","volume":"23","year":"1992","unstructured":"Gilman, J. T., and P. Gal. 1992. Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier. Clin. Pharmacokinet.23:1-9.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/157.1.14","volume":"157","year":"1988","unstructured":"Harris, C., M. P. Salgo, H. B. Tanowitz, and M. Wittner. 1988. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J. Infect. Dis.157:14-22.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00561477","volume":"18","year":"1980","unstructured":"Heimann, G. 1980. Enteral absorption and bioavailability in children in relation to age. Eur. J. Clin. Pharmacol.18:43-50.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0035-9203(90)90376-P","volume":"84","year":"1990","unstructured":"Hellgren, U., V. H. Angel, Y. Bergqvist, A. Arvidsson, J. S. Forero-Gomez, and L. Rombo. 1990. Plasma concentrations of sulfadoxine-pyrimethamine and of mefloquine during regular long term malaria prophylaxis. Trans. R. Soc. Trop. Med. Hyg.84:46-49.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0035-9203(91)90287-9","volume":"85","year":"1991","unstructured":"Hellgren, U., V. H. Angel, Y. Bergqvist, J. S. Forero-Gomez, and L. Rombo. 1991. Plasma concentrations of sulfadoxine-pyrimethamine, mefloquine and its main metabolite after regular malaria prophylaxis for two years. Trans. R. Soc. Trop. Med. Hyg.85:356-357.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1360"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003088-199223010-00002","volume":"23","year":"1992","unstructured":"Kauffman, R. E., and G. L. Kearns. 1992. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin. Pharmacokinet.23:10-29.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.48-51.2001"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.7.1623"},{"key":"e_1_3_1_28_2","first-page":"191","volume":"49","year":"1998","unstructured":"Laborie, I., V. Ratsimbazafy, M. Javerliat, and J. Buxeraud. 1998. Pr\u00e9vention de la toxoplasmose cong\u00e9nitale et de ses s\u00e9quelles. Lyon Pharm.49:191-203.","journal-title":"Lyon Pharm."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.1.26"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05381.x"},{"key":"e_1_3_1_31_2","first-page":"369","volume":"27","year":"1993","unstructured":"Marx, C., F. Foudrinier, T. Trenque, R. Fay, D. Dupouy, B. Leroux, C. Quereux, H. Choisy, M. Talmud, and J. M. Pinon. 1993. Toxoplasmose cong\u00e9nitale et dosage de la pyrim\u00e9thamine. Eurobiologiste27:369-374.","journal-title":"Eurobiologiste"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1040"},{"key":"e_1_3_1_33_2","unstructured":"Minist\u00e8re de l'Emploi et de la Solidarit\u00e9 Direction G\u00e9n\u00e9rale de la Sant\u00e9 Agence du M\u00e9dicament. 1998. Bonnes pratiques de fabrication. Bulletin Officiel 98-5 bis. Direction des Journaux Officiels Paris France."},{"key":"e_1_3_1_34_2","first-page":"328","volume":"71","year":"1994","unstructured":"Murphy, S. A., and E. Mberu. 1994. A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations. East Afr. Med. J.71:328-329.","journal-title":"East Afr. Med. J."},{"key":"e_1_3_1_35_2","first-page":"232","volume":"2","year":"2001","unstructured":"Murri, R., A. Ammassari, A. De Luca, A. Cingolani, P. Marconi, A. W. Wu, and A. Antinori. 2001. Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clin. Trials2:232-329.","journal-title":"HIV Clin. Trials"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/ajhp\/54.23.2714","volume":"54","year":"1997","unstructured":"Nahata, M. C., R. S. Morosco, and T. F. Hipple. 1997. Stability of pyrimethamine in a liquid dosage formulation stored for three months. Am. J. Health Syst. Pharm.54:2714-2716.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_1_37_2","first-page":"205","year":"2001","unstructured":"Remington, J. S., R. McLeod, P. Thulliez, and G. Desmonts. 2001. Toxoplasmosis, p. 205-346. In J. S. Remington and J. O. Klein (ed.), Infectious diseases of the fetus and newborn infant, 5th ed. W. B. Saunders, Philadelphia, Pa.","journal-title":"Infectious diseases of the fetus and newborn infant, 5th ed."},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2371"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00007691-199502000-00013","volume":"17","year":"1995","unstructured":"Ronn, A. M., M. M. Lemnge, H. R. Angelo, and I. C. Bygbjerg. 1995. High-performance liquid chromatography determination of dapsone, monoacetyldapsone, and pyrimethamine in filter paper blood spots. Ther. Drug Monit.17:79-83.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_1_40_2","first-page":"141","volume":"45","year":"1991","unstructured":"Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput.45:141-157.","journal-title":"Appl. Math. Comput."},{"key":"e_1_3_1_41_2","unstructured":"Sweetman S. (ed.). 2002. Martindale: the complete drug reference. Pharmaceutical Press London United Kingdom."},{"key":"e_1_3_1_42_2","first-page":"447","volume":"25","year":"1992","unstructured":"Thomson, A. H., and B. Whiting. 1992. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet.25:447-467.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059771"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s004310100805","volume":"160","year":"2001","unstructured":"Wallon, M., G. Cozon, R. Ecochard, P. Lewin, and F. Peyron. 2001. Serological rebound in congenital toxoplasmosis: long term follow-up of 133 children. Eur. J. Pediatr.160:534-540.","journal-title":"Eur. J. Pediatr."},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238505"},{"key":"e_1_3_1_46_2","first-page":"115","volume":"60","year":"1982","unstructured":"Weidekamm, E., H. Plozza-Nottebrock, I. Forgo, and U. C. Dubach. 1982. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. W. H. O.60:115-122.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1992.46.288","volume":"46","year":"1992","unstructured":"Weiss, L. M., B. J. Luft, H. B. Tanowitz, and M. Wittner. 1992. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am. J. Trop. Med. Hyg.46:288-291.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2165\/00003088-199426040-00006","volume":"26","year":"1994","unstructured":"Wilson, J. T., G. L. Kearns, D. Murphy, and S. J. Yaffe. 1994. Paediatric labelling requirements. Implications for pharmacokinetic studies. Clin. Pharmacokinet.26:308-325.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04016.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.10.3794-3800.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.10.3794-3800.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:29:17Z","timestamp":1645468157000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.10.3794-3800.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1128\/AAC.48.10.3794-3800.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.10.3794-3800.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"2003-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}